630 related articles for article (PubMed ID: 28651374)
1. CD70, a novel target of CAR T-cell therapy for gliomas.
Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
[TBL] [Abstract][Full Text] [Related]
2. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
3. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
[TBL] [Abstract][Full Text] [Related]
4. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
7. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
[TBL] [Abstract][Full Text] [Related]
8. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
9. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract][Full Text] [Related]
10. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.
Shaffer DR; Savoldo B; Yi Z; Chow KK; Kakarla S; Spencer DM; Dotti G; Wu MF; Liu H; Kenney S; Gottschalk S
Blood; 2011 Apr; 117(16):4304-14. PubMed ID: 21304103
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
[TBL] [Abstract][Full Text] [Related]
12. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
14. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.
Miller J; Eisele G; Tabatabai G; Aulwurm S; von Kürthy G; Stitz L; Roth P; Weller M
J Neurosurg; 2010 Aug; 113(2):280-5. PubMed ID: 19961309
[TBL] [Abstract][Full Text] [Related]
19. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]